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Available online 14 May 2016Baseline demographic and phenotypic characteristics of patients aged ≥50 years in the Fabry Outcome Survey
(Shire; data extracted June 2014)were comparedwith younger adults to investigate potential factors inﬂuencing
treatment decisions in later life. Age groupswere deﬁned using age at treatment initiation or at FOS entry for un-
treated patients: 18–49 (n = 1344; 49.5% male; 64.6% received agalsidase alfa enzyme replacement therapy
[ERT]); 50–64 (n = 537; 35.4% male; 74.3% treated); 65–74 (n = 137; 32.1% male; 68.6% treated); and
≥75 years (n= 26; 26.9% male; 50.0% treated). Successive age groups showed higher median age at ﬁrst symp-
tom and diagnosis. Median alpha-galactosidase A activity, measured as percentage activity of themidpoint of the
normal range, wasmuch greater in females thanmales of all groups except ≥75 years (33.4% in females; 27.8% in
males). Patients aged ≥75 years showed greater values than patients aged 18–49 years formedian left ventricular
mass indexed to height (62.7 vs 42.4 g/m2.7), mean ventricular wall thickness (15.0 vs 10.0 mm) and prevalence
of hypertension (57.7% vs 21.8%), and lowermedian estimated glomerular ﬁltration rate (Modiﬁcation of Diet in
Renal Disease: 65.6 vs 98.5mL/min/1.73m2). Larger proportions in the groups aged ≥50 exhibited cardiac and/or
cerebrovascular manifestations comparedwith patients aged 18–49 years. The smaller proportion of patients re-
ceiving ERT aged ≥75 years comparedwith the younger groupsmight reﬂect relatively milder disease burden or
physician/patient reluctance to initiate/continue ERT at this age. Further studies are needed to increase knowl-
edge of Fabry disease and ERT in later life.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Fabry disease results from a deﬁciency in lysosomal alpha-
galactosidase A (α-Gal A) due to mutations in the GLA gene. This leads
to the accumulation of globotriaosylceramide in cells and a multi-
system pathology.EPI, Chronic Kidney Disease
ﬁltration rate; ERT, enzyme re-
left ventricular hypertrophy;
Modiﬁcation of Diet in Renal
sorders Unit, Department of
and University College London,
. This is an open access article underDespite Fabry disease being X-linked, female heterozygotes can ex-
perience all of the signs and symptoms of the disease, but generally
later and with a milder, more variable phenotype than in males [1–4].
Females may, however, on occasions have a signiﬁcant burden of dis-
ease, similar to that observed in males [5,6]. The overall life expectancy
(calculated from birth) for patients with Fabry disease is 58 years for
men and 75 years for women [7].
Two broad phenotypes of Fabry disease are now recognised, the
classical form with childhood onset and multi-organ progression, and
a later-onset phenotype with limited organ involvement presenting in
middle age. In classical Fabry disease, α-Gal A activity is greatly dimin-
ished, at b1% of normal in males, whereas patients with later-onset car-
diac or renal variants tend to haveα-Gal A activity between 1% and 30%
[8]. Diagnosis of the later-onset variant may be delayed due to lack of
obvious external symptoms and signs such as acroparesthesia and
angiokeratoma. In all Fabry disease phenotypes, the natural history ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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which themselves become more severe and prevalent with age.
Enzyme replacement therapy (ERT) in Fabry disease is expected to
be most successful when started early in the disease course [9–11]; its
initiation has been recommended as soon as early clinical signs of kid-
ney, heart or brain involvement consistent with Fabry disease become
apparent [12].
Family screening and symptom-based screening programmes have
identiﬁed people with Fabry disease in later-life stages and it is unclear
whether the rationale for starting treatment in this more advanced age
group should be the same as for index cases diagnosed at a younger age.
Symptom-based therapy in these older patientsmay bemore beneﬁcial,
more cost effective and less burdensome to the health care provider
than starting ERT to prevent Fabry disease progression and clinical
events. Few studies focusing on elderly patients with Fabry disease
have been performed; one analysis of six patients indicated limited ben-
eﬁt in starting/continuing ERT in elderly patients in terms of life expec-
tancy and cost-effectiveness [13].
The objective of the present analysis was to describe the demo-
graphic and phenotypic characteristics of patients who were
≥50 years of age in the Fabry Outcome Survey (FOS) and to compare
them with younger adult patients in an attempt to identify any factors
that might inﬂuence the decision to treat, or not to treat, at later stages
in life.
2. Methods
This was a retrospective analysis of data entered in FOS, a global, ob-
servational registry sponsored by Shire for the collection of outcomes
data on Fabry disease. A diagnosis of Fabry disease is conﬁrmed by re-
duced alpha-galactosidase A activity in plasma and leukocytes in
males, and by molecular analysis to conﬁrm GLAmutations in females
and males. All patients with a conﬁrmed diagnosis of Fabry disease
who are receiving, or are eligible for ERTwith agalsidase alfa, can be reg-
istered in FOS. Patients who are currently receiving ERT with a drug
other than agalsidase alfa are not eligible for inclusion in FOS. Data col-
lection in FOSwas initiated in 2001, and all patients aged ≥18 yearswith
data entered in FOS at the time of extraction (June 2014)were included.
The institution review boards of each participating centre approved
FOS and all patients provided written informed consent prior to
enrollment.
2.1. Populations analyzed
To analyze the presentation and clinical characteristics of elderly pa-
tients the population in FOS was divided into the following age groups:
patients 18–49 years, 50–64 years, 65–74 years and ≥75 years (elderly
group). The groups were stratiﬁed by age at treatment initiation for
treated patients and age at FOS entry for untreated patients. Treated pa-
tients received agalsidase alfa 0.2mg/kg bodyweight every other week.
2.2. Parameters evaluated
Patient demographics and the following baseline clinical character-
istics were compared between the age groups: cardiac parameters (ob-
tained via echocardiography, according to the American Society of
Echocardiography recommendations) [14]: left ventricular mass
indexed to height (LVMI), left ventricular hypertrophy (LVH; N48 g/
m2.7 in females and N50 g/m2.7 in males), mean ventricular wall thick-
ness (MWT), aortic root diameter; renal parameters: serum creatinine,
estimated glomerular ﬁltration rate (eGFR) using the Modiﬁcation of
Diet in Renal Disease (MDRD) formula, Chronic Kidney Disease Epide-
miology Collaboration (CKD EPI) equation, urine protein. Chronic kid-
ney disease staging according to KDIGO guidelines [15] was
performed for patients who had both eGFR and albumin data available
(Supplementary data Fig. S1).Baseline cardiac, renal, cerebrovascular and auditory signs/symp-
toms were also compared between the age groups of the overall
population.2.3. Statistical analysis
Descriptive statistics were calculated for all continuous and categor-
ical variables to enable a thorough description of the demographic and
clinical characteristics of patients aged ≥50 years.3. Results
3.1. Enrollment and demographics
As of June 2014, a total of 2338 patients were enrolled in FOS (1279
females and 1059males); 2044 of thesewere aged ≥18 years and are in-
cluded in the current study. This study focuses on age rather than gen-
der; however, data stratiﬁed by both age and gender are provided for
reference in Supplementary data Tables S1–S4.
The proportion of females increased with successive age group
(Table 1). The proportions of patients treated with ERT were 64.6%
aged 18–49 years, 74.3% aged 50–64, 68.6% aged 65–74 and 50.0%
aged ≥75 years (Table 1).
Median age at ﬁrst symptom and diagnosis increasedwith each suc-
cessive age group, whereas the median delay in diagnosis was similar
between the groups aged 50–64 and 65–74 years (Table 1).
Medianα-Gal A activity,measured as percentage activity of themid-
point of the normal range, was similar in females regardless of age, and
generallymuchhigher than inmales. In the elderly group,α-Gal A activ-
ity was at its highest in males (27.8% [13.6–42.0%]) and thus closer to
the level observed in females (33.4% [1.1–487.9%]; Table 1).
The largest proportion of Fabry disease diagnoses in each age group
wasmade as a result of familymembers being affected. Of the specialists
who ﬁrst suspected Fabry disease, cardiologists diagnosed the largest
proportions of patients in all groups aged ≥50 years. Nephrologists diag-
nosed the largest proportion of patients aged 18–49 years (Table 1).
The majority of patients were negative for heart pacemaker/trans-
plant/deﬁbrillator use at any time (Table 1). Therapy with
angiotensin-converting enzyme inhibitors and/or angiotensin receptor
blockers was more prevalent in patients who were aged ≥50 years
than in younger adults (Table 1). Diabetes mellitus was more prevalent
in patients aged ≥50 years than in younger adults (6.1% aged 50–64;
10.9% aged 65–74 and 3.8% aged ≥75 years vs 1.4% aged 18–49 years),
and hypertension prevalence decreased with decreasing age group
(57.7% aged ≥75 years; 48.2% aged 65–74; 41.9% aged 50–64; 21.8%
aged 18–49; Table 1).3.2. Phenotypic characteristics
3.2.1. Baseline cardiac parameters and events
A higher median baseline LVMI was demonstrated by Fabry patients
presenting at amore advanced age than in the youngest group (Fig. 1A).
Similarly, median MWT was progressively higher in the older groups
(Fig. 1B).
Median aortic root diameter was similar for each of the age groups
(see Supplementary data Table S2 for aortic root diameter by gender).
The rate of cardiac events/manifestations experienced before treat-
ment initiation or FOS entry was greater in patients aged N50 years,
where similar rates were experienced by the groups aged 50–64
(81.0%) and 65–74 (80.3%), and the highest rate (88.5%) by the elderly
group. Fewer patients experienced any cardiac event/manifestation in
the youngest group (58.6%; Table 2). Left ventricular hypertrophy was
the most prevalent cardiac manifestation in each age group (Table 2).
Table 1
Summary of demographics and general clinical characteristics of the overall FOS population, stratiﬁed by age group (and gender for α-Gal A activity).
Parameter 18–49 years 50–64 years 65–74 years ≥75 years
Overall N= 1344 N= 537 N= 137 N= 26
Males, n (%) 679 (50.5) 347 (64.6) 93 (67.9) 19 (73.1)
Females, n (%) 665 (49.5) 190 (35.4) 44 (32.1) 7 (26.9)
Treated, n (%) 868 (64.6) 399 (74.3) 94 (68.6) 13 (50.0)
Males, n (%) 572 (65.9) 161 (40.4) 30 (31.9) 3 (23.1)
Females, n (%) 296 (34.1) 238 (59.6) 64 (68.1) 10 (76.9)
Age (years) at ﬁrst symptom
N (missing) 857 (487) 315 (222) 77 (60) 15 (11)
Mean (SD) 16.6 (11.9) 32.2 (18.8) 47.8 (19.2) 53.8 (23.8)
Median (range) 12.0 (0.0–49.0) 34.0 (0.0–63.0) 54.0 (4.0–71.0) 64.0 (4.0–75.0)
Age (years) at diagnosis
N (missing) 1276 (68) 505 (32) 128 (9) 25 (1)
Mean (SD) 28.3 (11.5) 50.1 (11.2) 63.4 (10.3) 70.3 (13.1)
Median (range) 29.0 (0.0–50.0) 52.0 (4.0–64.0) 66.0 (11.0–74.0) 75.0 (36.0–85.0)
Delay (years) between symptom and
diagnosis
N (missing) 847 (497) 311 (226) 75 (62) 15 (11)
Mean (SD) 10.9 (12.0) 16.3 (17.2) 14.7 (18.0) 12.8 (25.7)
Median (range) 8.0 (−33.0–41.0) 11.0 (−25.0–55.0) 10.0 (−35.0–62.0) 6.0 (−27.0–68.0)
Age (years) at start of agalsidase alfa
N (missing) 868 (476) 399 (138) 94 (43) 13 (13)
Mean (SD) 35.2 (9.2) 56.6 (4.1) 69.1 (2.8) 77.7 (1.9)
Median (range) 35.6 (18.0–49.9) 56.3 (50.0–64.9) 68.6 (65.0–75.0) 78.7 (75.0–80.8)
Time (years) to follow up
N (missing) 1344 (0) 537 (0) 137 (0) 26 (0)
Mean (SD) 3.8 (3.4) 2.9 (3.0) 2.5 (2.5) 1.8 (2.4)
Median (range) 2.9 (0.0–12.4) 1.9 (0.0–12.1) 1.7 (0.0–10.1) 0.9 (0.0–10.5)
Relatives in the cohort, n (%) 645 (48.0) 222 (41.3) 56 (40.9) 16 (61.5)
α-Gal A (% midpoint normal range) Male Female Male Female Male Female Male Female
N (missing) 288 (377) 323 (356) 87 (103) 158 (189) 21 (23) 33 (60) 2 (5) 11 (8)
Mean (SD) 6.3 (7.6) 51.5 (36.6) 8.1 (9.6) 52.4 (35.1) 10.3 (13.8) 60.4 (60.7) 27.8 (20.1) 89.7 (142.0)
Median (range) 4.0
(0.0–66.7)
44.0
(0.1–212.0)
5.2
(0.0–50.0)
47.6
(0.1–181.8)
7.7
(0.2–67.0)
44.0
(0.2–251.5)
27.8
(13.6–42.0)
33.4
(1.1–487.9)
Specialist who ﬁrst suspected disease, n (%) 414 182 45 6
Affected family member 470 (50.5) 139 (39.2) 38 (41.3) 11 (55.0)
Cardiologist 41 (4.4) 52 (14.6) 24 (26.1) 4 (20.0)
Dermatologist 39 (4.2) 14 (3.9) – –
Gastroenterologist 1 (0.1) 1 (0.3) – –
General practitioner 32 (3.4) 9 (2.5) 2 (2.2) –
Geneticist 37 (4.0) 42 (11.8) 6 (6.5) 4 (20.0)
Internist 21 (2.3) 8 (2.3) 3 (3.3) –
Nephrologist 120 (12.9) 30 (8.5) 7 (7.6) 1 (5.0)
Neurologist 37 (4.0) 18 (5.1) 1 (1.1) –
Ophthalmologist 52 (5.6) 17 (4.8) 3 (3.3) –
Other 36 (3.9) 19 (5.4) 6 (6.5) –
Paediatrician 38 (4.1) 4 (1.1) 2 (2.2) –
Rheumatologist 6 (0.6) 2 (0.6) – –
ARB/ACE therapy any time, n (%) 408 (30.4) 238 (44.3) 72 (52.6) 10 (38.5)
Heart pacemaker/transplant/deﬁbrillator, n
(%)
10 (0.7) 21 (3.9) 4 (2.9) 2 (7.7)
Currently smoking, n (%) 103 (7.7) 28 (5.2) 2 (1.5) –
Smoking history, n (%) 171 (12.7) 78 (14.5) 18 (13.1) 5 (19.2)
Diabetes mellitus, n (%) 19 (1.4) 33 (6.1) 15 (10.9) 1 (3.8)
Hypertension, n (%) 293 (21.8) 225 (41.9) 66 (48.2) 15 (57.7)
Obesity (≥35 kg/m2), n (%) 38 (2.8) 23 (4.3) 4 (2.9) 1 (3.8)
Tortuous vessels, n (%) 213 (15.8) 60 (11.2) 15 (10.9) 1 (3.8)
Angiokeratoma, n (%) 642 (47.8) 194 (36.1) 48 (35.0) 5 (19.2)
Raynaud Syndrome, n (%) 124 (9.2) 46 (8.6) 13 (9.5) 1 (3.8)
Malignancy, n (%) 17 (1.3) 24 (4.5) 9 (6.6) 5 (19.2)
Deceased recorded in database, n (%) 41 (3.1) 39 (7.3) 13 (9.5) 4 (15.4)
ACE = angiotensin-converting enzyme inhibitor; α-Gal A = alpha-galactosidase A; ARB = angiotensin receptor blocker.
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Median serum creatinine was similar in all age groups: 0.8
(range 0.4–14.6), 0.9 (0.3–13.7), 1.0 (0.5–11.7) and 0.9 (0.6–10.3)
mg/dL in patients aged 18–49, 50–64, 65–74 and ≥75 years,
respectively.
As expected, median eGFR calculated using the MDRD equation
showed a decrease with increasing age group and was lowest in the el-
derly group (Fig. 1C).
Similarly, median (range) eGFR calculated using the CKD-EPI formu-
la also showed a decrease with increasing age group, from 107.0
(0.0–172.6) mL/min/1.73 m2 in patients aged 18–49 to 82.1(3.0–117.7), 68.1 (3.9–101.4) and 60.8 (4.4–89.6) mL/min/1.73 m2 in
patients aged 50–64, 65–74 and ≥75 years, respectively.
Median urine protein levels were 168.2 (range 0.0–4900.0), 148.2
(20.0–4640.0) and 110.0 (47.6–2010.0) mg/24 h in the groups aged
50–64, 65–74 and ≥75 years, respectively, compared with 167.0
(0.0–9690.0) mg/24 h in the youngest group.
Any renal event/manifestation was experienced by a similar per-
centage of patients in each of the age groups: 46.0% in patients aged
18–49 years, and 49.9%, 46.0% and 46.2% in patients aged 50–64,
65–74 and ≥75 years, respectively. Proteinuria/microalbuminuria was
the most prevalent renal manifestation in all age groups (Table 2).
Fig. 1. Box plots showing A. Left ventricular mass indexed to height. B. Mean ventricular
wall thickness. C. Estimated glomerular ﬁltration rate (eGFR) using the Modiﬁcation of
Diet in Renal Disease formula (MDRD) for the patients in each age group.
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summarized in Supplementary data Fig. S1.3.2.3. Isolated cardiac and renal manifestations
The proportion of patients who reported isolated cardiac manifesta-
tions (deﬁned as LVH but no proteinuria) was highest in the elderly
group (61.5%; n = 16) and decreased with decreasing age: 39.4%
(n = 54), 38.5% (n = 207) and 16.9% (n = 227) in the groups aged
65–74, 50–64 and 19–50 years, respectively.
Conversely, the proportion of patients with isolated renalmanifesta-
tions (deﬁned as proteinuria but no LVH) was lowest in the elderly
group (3.8%; n= 1) and increased with decreasing age: 4.4% (n = 6),
7.1% (n = 38) and 18.8% (n = 253) in the groups aged 65–74, 50–64
and 18–49 years.3.2.4. Cerebrovascular events
Any cerebrovascular event/manifestation was reported by a greater
proportion of patients in the groups aged 50–64 (24.2%), 65–74 (27.7%)
and ≥75 years (19.2%) than in the youngest group (17.1%). Stroke was
most prevalent in the groups older than 50 years (Table 2).
3.2.5. Auditory events
A larger proportion of patients in the elderly group (57.7%) experi-
enced auditory events/manifestations than in the youngest group
(45.7%). Hearing impairment was most prevalent in the elderly group
(Table 2).
4. Discussion
This study analyzed data collected in FOS to investigate whether a
demographic and phenotypic description could be made of patients
aged ≥50 years that differentiate them from younger adult patients.
This analysis showed that a smaller proportion of older patients
were treated with ERT and that, after 50 years of age, the majority of
ERT initiations were made in female patients (Table 1). This indicates
a possible reluctance of physicians and patients to commence and/or
continue ERT at older ages. The decision to either initiate or continue
long-term ERT in patients with Fabry disease who are aged ≥50 years
must take into account potential treatment beneﬁts over costs to the
healthcare system, and quality of life. Factors for consideration regard-
ing ERT initiation in elderly patients are outlined in Fig. 2 [16].
Since Fabry disease is a progressive disorder, disease severity and the
degree of organ involvement increase with age. Several recent reports
have indicated that ERT in patients with advanced disease has limited
effectiveness [17–19], especiallywhen initiated after ﬁbrosis has started
to develop in the heart, kidney or central nervous system, which may
occur at a relatively early age in Fabry disease [20]. One study on pa-
tients whowere slightly older (40± 9 years) than in previously studied
groups, andwhowere thus likely to havemore advanced disease, found
that disease progression towards organ failure and deathwas not halted
by ERT over a period of approximately 6 years [18]. Initiating/continuing
ERT in patients with Fabry disease who are ≥75 years may not be bene-
ﬁcial in terms of life expectancy or cost effectiveness [13]. The number
of years since symptom onset or diagnosis may be a better predictor
of ERT refractory disease than simply age.
The cardiac and renal signs and symptoms observed in the analysis
population aged ≥50 yearswere generally non-speciﬁc and could reﬂect
the natural aging process. For example, compared with patients aged
18–49 years, older patients had a greater prevalence of cardiac events/
manifestations such as LVH and arrhythmia, decreases in eGFR and in-
creased prevalence of hearing impairment. Hearing loss, a common oc-
currence during natural aging, was previously found to be
independently predictive of cardiac, renal and cerebrovascular compli-
cations in Fabry disease [21] and was the most prevalent auditory
event in the current study. Microalbuminuria is a known cardiovascular
risk factor in patients with hypertension [22], and microalbuminuria
and proteinuria were the most prevalent renal manifestations in each
age group in the current analysis. While the prevalence of hypertension
increased with successive age group, the prevalence of
microalbuminuria and proteinuria did not. Since the groups were strat-
iﬁed by age at treatment initiation or FOS entry in untreated patients,
thisﬁndingmay reﬂect a lower burden frommicroalbuminuria/protein-
uria and a milder Fabry disease phenotype in the older age groups than
the younger group.
Whether patients have classical or later-onset Fabry disease may
also require consideration whenmaking decisions regarding ERT initia-
tion/continuation. We found that age at symptom onset generally in-
creased with successive age group. These data were collected via
patient recall, and thus must be interpreted carefully, but this increase
may reﬂect a predominance of de novo diagnosis of the later-onset phe-
notype in the groups aged ≥50 years, rather than long-lived patients
Table 2
Summary of cardiac, renal, cerebrovascular and auditory events/manifestations among the overall FOS population, stratiﬁed by age group.
Parameter
18–49 years
(n= 1344)
50–64 years
(n= 537)
65–74 years
(n= 137)
≥75 years
(n= 26)
Any cardiac
event/manifestation, n (%)
787 (58.6) 435 (81.0) 110 (80.3) 23 (88.5)
Conduction abnormality 94 (7.0) 80 (14.9) 26 (19.0) 6 (23.1)
Fatigue 317 (23.6) 129 (24.0) 40 (29.2) 10 (38.5)
LVH 431 (32.1) 336 (62.6) 93 (67.9) 20 (76.9)
Heart failure 205 (15.3) 122 (22.7) 42 (30.7) 9 (34.6)
Arrhythmia 120 (8.9) 111 (20.7) 49 (35.8) 13 (50.0)
Cardiac surgery 15 (1.1) 29 (5.4) 10 (7.3) 4 (15.4)
Palpitations 220 (16.4) 111 (20.7) 27 (19.7) 6 (23.1)
Angina 44 (3.3) 54 (10.1) 18 (13.1) 1 (3.8)
Valve disease 125 (9.3) 75 (14.0) 24 (17.5) 7 (26.9)
Cardiac syncope 28 (2.1) 17 (3.2) 3 (2.2) 4 (15.4)
Dyspnea 131 (9.7) 108 (20.1) 39 (28.5) 7 (26.9)
Other (than listed) 129 (9.6) 115 (21.4) 33 (24.1) 6 (23.1)
Any renalevent/manifestation, n (%) 618 (46.0) 268 (49.9) 63 (46.0) 12 (46.2)
Microalbuminuria 222 (16.5) 74 (13.8) 23 (16.8) 5 (19.2)
Peritoneal dialysis 8 (0.6) 2 (0.4) – –
Proteinuria 457 (34.0) 167 (31.1) 45 (32.8) 5 (19.2)
Hematuria 82 (6.1) 29 (5.4) 7 (5.1) 1 (3.8)
Other (than listed) 79 (5.9) 56 (10.4) 18 (13.1) 4 (15.4)
Renal failure 116 (8.6) 71 (13.2) 18 (13.1) 2 (7.7)
Hemodialysis 42 (3.1) 19 (3.5) 2 (1.5) –
Transplants 30 (2.2) 20 (3.7) 2 (1.5) –
Unspeciﬁed dialysis 36 (2.7) 21 (3.9) 2 (1.5) 2 (7.7)
Any cerebrovascular event/manifestation, n (%) 230 (17.1) 130 (24.2) 38 (27.7) 5 (19.2)
TIA 49 (3.6) 32 (6.0) 7 (5.1) 1 (3.8)
Other (than listed) 122 (9.1) 44 (8.2) 14 (10.2) 2 (7.7)
Stroke 96 (7.1) 73 (13.6) 26 (19.0) 4 (15.4)
PRIND 4 (0.3) 5 (0.9) – –
Any auditory
event/manifestation, n (%)
614 (45.7) 256 (47.7) 64 (46.7) 15 (57.7)
Tinnitus 400 (29.8) 123 (22.9) 27 (19.7) 6 (23.1)
Vertigo 318 (23.7) 132 (24.6) 31 (22.6) 4 (15.4)
Sudden deafness 43 (3.2) 19 (3.5) 4 (2.9) 1 (3.8)
Hearing impairment 297 (22.1) 156 (29.1) 45 (32.8) 13 (50.0)
Other (than listed) 31 (2.3) 20 (3.7) 7 (5.1) 3 (11.5)
LVH= left ventricular hypertrophy; PRIND = prolonged reversible neurological deﬁcits; TIA = transient ischemic attack.
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tended to increase with successive age group and each group also expe-
rienced delays in diagnosis, as found previously [3,4]. The delay in diag-
nosis doubled between the ages of 50 and 74 years, possibly because
patients presenting in these groups had limited disease with fewer
symptoms characteristic of Fabry disease. Angiokeratoma and tortuousFig. 2. Considerations in the decision to initiate ERT in patients with Fabry diseasewho are
older than 50 years.ocular vessels, which may facilitate Fabry disease diagnosis, were
more prevalent in patients aged 18–49 years than in the older age
groups. Since the level of tortuosity is positively correlated with disease
severity [23], this could provide further evidence of limited disease in
our population aged ≥50 years.
Age at onset in patients with cardiac variant Fabry disease is report-
ed to be in the sixth to eighth decade [8]. In our study, compared with
the younger adult group, the prevalence of cardiac events/manifesta-
tions was greater in patients aged 65–74 and ≥75 years, whereas that
of renal events/manifestations generally remained similar or was
lower. The cardiac events in this group may be linked to the aging pro-
cess or theymight indicate a larger proportion of patients aged 65 years
and above with the later-onset cardiac variant of Fabry disease. If the
main value of ERT is considered to be preventing signiﬁcant clinical
events that might only occur years hence resulting from a lifetime of
storage deposition and secondary organ pathology, then the value of
ERT in these patients may be limited. However, it remains possible
that, for those experiencing Fabry symptoms not alleviated by conven-
tional therapies, ERT might have a role in immediate symptomatic ben-
eﬁt. An improvement in symptoms has been reported when ERT is
started in younger patients [24], but the efﬁcacy of ERT in later-onset
Fabry disease still needs to be formally determined and a regimen for
optimal supportive care and symptom control carefully considered.
Similarly, in classical patients receiving long-term ERT, there is likely
to come a point at which supportive and symptomatic care becomes
more important than limited ERT for long-term organ protection.
Therewere a number of limitations in our study. FOS is a rare disease
registry, and thus contains a relatively small number of patients, espe-
cially in the older age groups. However, few exclusion criteria were
324 O. Lidove et al. / Molecular Genetics and Metabolism 118 (2016) 319–325applied; therefore the patient population was not highly selected. Fur-
thermore, a decline in number with aging would be expected in a con-
trol population, although the low numbers did limit us to the use of
descriptive statistics only, making it difﬁcult to draw conclusions from
the data. The possibility of errors incurred during data entry cannot be
completely ruled out. While some values appeared to be high (for ex-
ample, upper range value for urine protein of 9690.0 mg/24 h in the
youngest group), these were considered to be within clinically feasible
ranges; those that were deemed implausible were excluded from anal-
ysis. Also, due to somemissing data, the trends observedwill need to be
followed up in order to be conﬁrmed.Deﬁnitions of signs and symptoms
are not provided in FOS and thus are not standardized across participat-
ing centres. Each physician determines their presence at patient visits
according to predetermined criteria and records this information in
the database primarily as “YES” or “NO” variables. Further information
on particular signs and symptoms is sparse, which imposes some re-
strictions on the analyses that can subsequently be performed. It should
also be noted that standardized methods for measuring the clinical pa-
rameters are not currently speciﬁed within FOS. A further possible lim-
itation is that genetics data were not available for inclusion; however,
this paper represents a phenotypic analysis and reports data, including
residual α-Gal A activity data, from a large number of patients. Muta-
tions associated with later-onset variants of Fabry disease could prove
to be an interesting focus for future studies.
5. Conclusions
This is the ﬁrst report to date analyzing the phenotype of Fabry dis-
ease in patients aged ≥50 years. Some elderly patients who are
experiencing Fabry-related complications and who are eligible for ERT
are not receiving it. Further studies are required to delve deeper into
the reasons behind this, to show what types of supportive care are
being provided instead of or as well as ERT, and also to better deﬁne
those who are suitable for ERT. Although there may be limited beneﬁts
in initiating or continuing ERT in older patients with more advanced
Fabry disease, further investigations are warranted, particularly in
older patientswith later-onset diseasewhomay showa slower progres-
sion of Fabry manifestations.
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